Floatz logo

Zeprumetostat

Platinum-sensitive Recurrent

Peking University Third HospitalSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Platinum-sensitive Recurrent cohort.

Asset / SponsorPhaseRating
Fuzuloparib
Peking University Third Hospital
Phase 2CCC

Same molecule, other indications

Zeprumetostat is also rated in:

Chronic Postsurgical PainDormant
B
Indicative ·
60 / 100
View asset →
Obese Patients With Prostate Cancer DiseaseDormant
B
Indicative ·
60 / 100
View asset →
peripheral T-cell lymphoma, not otherwise specifiedDormant
B
Indicative ·
58 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →